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ABSTRACT
Background. This study compared the effects of short-term
titrated colestilan (a novel non-absorbable, non-calcium,
phosphate binder) with placebo, and evaluated the safety and
efficacy of colestilan over 1 year compared with sevelamer, in
patients with chronic kidney disease (CKD) 5D.
Methods. This prospective multicentre study comprised a
4-week phosphate binder washout period, a 16-week short-
term, flexible-dose, treatment period (including a 4-week
placebo-controlled withdrawal period) and a 40-week exten-
sion treatment phase.
Results. At Week 16 (the end of the 4-week placebo-controlled
withdrawal period), serum phosphorus level was 0.43 mmol/L
(1.32 mg/dL) lower with colestilan than placebo (P < 0.001;
primary end point). Serum LDL-C level was also lower with
colestilan than with placebo (P < 0.001). Both colestilan and
sevelamer produced significant reductions from baseline in
serum phosphorus levels (P < 0.001), maintained for 1 year,
and the proportion of patients achieving target levels of ≤1.78
mmol/L (5.5 mg/dL) or ≤1.95 mmol/L (6.0 mg/dL) at study
end were similar (65.3 and 73.3%, respectively, for colestilan,
and 66.9 and 77.4%, respectively, for sevelamer). Serum
calcium level remained stable in the colestilan group but
tended to increase slightly in the sevelamer group (end-of-
study increase of 0.035 mmol/L over baseline). Both binders
produced similar reductions from baseline in LDL-C level (P
< 0.001), and responder rates after 1 year, using a target
of <1.83 mmol/L (70 mg/dL) or <2.59 mmol/L (100 mg/dL)
were similar in both groups (50.7 and 85.3% for colestilan and
54.0 and 80.6% for sevelamer). Colestilan was generally well
tolerated.
Conclusions. Colestilan is effective and safe for the treatment
of hyperphosphataemia in patients with CKD 5D, and affords
similar long-term phosphorus and cholesterol reductions/re-
sponder rates to sevelamer.
Keywords: chronic kidney disease, colestilan, hyperphospha-
taemia, placebo, sevelamer
INTRODUCTION
In patients with chronic kidney disease (CKD), hyperpho-
sphataemia plays a role in the development of secondary
hyperparathyroidism, CKD-bone mineral disorder and soft
tissue and vascular calcification [1–3], and is associated with
an increased risk of cardiovascular disease and death [4, 5].
Treatment with oral phosphate binders, which act by binding
dietary phosphate in the intestines to prevent its absorption,
often forms part of the management strategy to reduce and
control serum phosphorus levels in patients with advanced
CKD [6]. Data from observational studies suggest that the use
of phosphate binders prolongs survival in patients receiving
haemodialysis [7–9].
Phosphate binders are theoretically all effective at lowering
phosphorus levels. However, factors such as pill burden and
compliance impact on the efficacy achieved in practice, and
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other characteristics, such as safety and tolerability, or add-
itional beneficial effects, may help determine the choice of
agent [10]. For example, it has been reported on many occa-
sions that calcium-based phosphate binders can increase the
risk of calcium overload and vascular calcification [2, 11, 12],
whereas non-calcium-based phosphate binders such as
sevelamer or lanthanum reduce the risk of hypercalcaemia
[13], and potentially of vascular calcification [14–16].
Sevelamer has also been shown to improve the lipid profile
in patients with CKD on dialysis (CKD 5D) compared with
calcium-based binders [17, 18]. Dyslipidaemia is common in
patients with CKD, and may contribute to the risk of cardio-
vascular disease in some patients [19]. Moreover, CKD is itself
considered to be a coronary heart disease risk-equivalent, and
it is recommended that lipid disorders are treated in such pa-
tients [20–22].
Colestilan is a new, non-absorbable, non-calcium, non-
metal, anion-exchange resin that binds both phosphorus and
bile acids in the gastrointestinal tract [23]. Short-term, fixed-
dose, phase III clinical trials in dialysis patients have shown
that colestilan is effective at lowering both serum phosphorus
and low-density lipoprotein levels [24].
The current study was undertaken to evaluate the effects of
short-term titrated colestilan versus placebo on serum phos-
phorus and lipid levels in patients with CKD 5D, and to evalu-
ate the safety and efficacy of colestilan over a 1-year period
with sevelamer as a comparator arm. The study comprised two
main parts. The primary aim of the initial short-term phase
(where, following a 12-week open-label titration period, pa-
tients were randomized in a double-blind manner to continue
on colestilan treatment or swap to placebo) was to
demonstrate that colestilan was superior to placebo in the
control of serum phosphorus levels in patients with CKD 5D
and hyperphosphataemia. The primary aim of the subsequent
extension phase was to evaluate the long-term safety and toler-
ability of colestilan. Secondary aims included an assessment of
the long-term efficacy of colestilan with regard to hyper-
phosphataemia and dyslipidaemia, and a comparison of the
efficacy and safety of colestilan with that of sevelamer. The
current report focuses on efficacy data; long-term safety and
tolerability data will be presented in a separate paper.
MATERIALS AND METHODS
Study design and setting
This prospective, multicentre study comprised a 16-week
short-term treatment phase (incorporating a 12-week flexible-
dose treatment period followed by 4-week placebo-controlled
withdrawal period) and a 40-week long-term extension treat-
ment phase. The primary aim of the short-term phase was to
compare colestilan with placebo during the placebo-controlled
withdrawal period (Figure 1). The primary aim of the exten-
sion treatment phase was to evaluate the long-term safety of
colestilan; efficacy was assessed as a secondary end point.
After a 4-week phosphate binder washout period, patients
were randomized 1:1 to receive 12 weeks of open-label treat-
ment with colestilan or sevelamer. Patients in the colestilan
group who completed the open-label period were re-rando-
mized to either continue on the same dose of colestilan or
switch to placebo for a 4-week, double-blind, placebo-con-
trolled withdrawal period. All patients who completed the
short-term phase were eligible to enter the 40-week extension
phase, meaning that patients were exposed to colestilan for up
to either 52 or 56 weeks in total, or to sevelamer for up to
52 weeks.
During the initial titration period, the starting dose of co-
lestilan was 6 g/day (i.e. 6 tablets, 2 tablets t.i.d.). Titration up
or down was allowed every 3 weeks within the range 3–15 g/day
(using 3 g increments) with the aim of achieving and main-
taining serum phosphorus levels between 1.13 mmol/L (3.5
mg/dL) and 1.78 mmol/L (5.5 mg/dL). The starting dose of
sevelamer was 2.4 g/day (i.e. 3 tablets) if serum phosphorus
was ≤2.42 mmol/L (7.5 mg/dL) or 4.8 g/day (i.e. 6 tablets) if
serum phosphorus was >2.42 mmol/L (7.5 mg/dL), with titra-
tion up or down between 2.4 and 12 g/day. During the
extension phase, patients who had been on sevelamer in the
short-term phase continued on the same dose, while patients
who had originally been in the colestilan group started on co-
lestilan 6 g/day. For both groups, dose titration was allowed
every 2 weeks for the first 8 weeks of the extension and then 4-
-weekly, to maintain serum phosphorus levels ≤1.78 mmol/L
(5.5 mg/dL).
The study was performed at 69 sites in Australia, Austria,
the Czech Republic, France, Germany, Hungary, Italy, Poland,
South Africa, Spain and the United Kingdom.
Patients were randomized according to a centrally gener-
ated randomization code, which was designed per centre to
ensure each site enrolled approximately equal numbers to each
treatment group.
The study was conducted in accordance with the principles
of the Declaration of Helsinki, and the International Confer-
ence on Harmonisation (ICH) guidelines on Good Clinical
Practice (GCP), and was approved by the relevant Independ-
ent Ethics Committee for each site. All patients provided their
written informed consent before entering the study. The study
was registered in the EudraCT database (2006-003323-37).
F IGURE 1 : Study design (COL = colestilan, PL = placebo, SEV = sevelamer).
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Patients
The study enrolled male or females aged ≥18 years of age
with CKD 5D. Patients had to have stable phosphate control
using phosphate-binding medication for at least 1 month prior
to screening, and to have a serum phosphorus level <2.42
mmol/L (7.5 mg/dL) at screening. The calcium dialysate
content had to be between 2 and 3.5 mEq/L and to remain
constant throughout the study. Furthermore, to qualify for
randomization serum phosphorus had to be ≥1.94 mmol/L
(6.0 mg/dL) and at least 15% greater than at screening, after
both 2 and 3 weeks of phosphate binder washout, or ≥2.58
mmol/L (8.0 mg/dL) and at least 15% greater than at screening
after 1 week of washout.
The main exclusion criteria were: clinically significant
medical comorbidities which could substantially compromise
patient safety or interfere with study procedures, serum
albumin level <30.0 g/L, intact parathyroid hormone (iPTH)
levels consistently/frequently >1000 pg/mL, body mass index
(BMI) ≤16.0 or ≥40.0 kg/m2, a history of significant gastro-
intestinal abnormalities including motility problems or major
gastrointestinal surgery, biliary obstruction or proven liver
dysfunction or liver function tests three times the upper limit
of normal for at least two of alanine aminotransferase, aspar-
tate aminotransferase and gamma-glutamyl transferase.
Study end points
The primary end point of the short-term phase was the
change in serum phosphorus level in the colestilan and
placebo groups during the placebo-controlled withdrawal
period (Week 12 to Week 16). Secondary end points included
changes in other efficacy parameters (including calcium,
calcium × phosphorus ion product [Ca × P], iPTH, lipid
parameters and uric acid) and safety parameters during the
placebo-controlled withdrawal period, and changes in serum
phosphorus level in the colestilan and sevelamer groups
during the open-label titration period (baseline to Week 12).
Glycosylated haemoglobin (HbA1c) was also evaluated.
The primary end point for the long-term extension was the
incidence of adverse events (AEs) and changes in safety para-
meters with colestilan and sevelamer. Efficacy parameters were
evaluated as secondary end points.
Sample size
For the primary end point (change in serum phosphorus
level during the placebo-controlled withdrawal period), 22
subjects per group were required, assuming a difference
between colestilan and placebo of ≥0.5 mmol/L (1.5 mg/dL)
with a standard deviation (SD) of 0.5 mmol/L, a 10% dropout
rate, a significance level set at 5% and statistical power of 80%.
For the comparison of colestilan and sevelamer during the
active comparator phase, 160 subjects per group were required,
assuming the lower bound of the 90% confidence interval (CI)
for the difference in change in serum phosphorus level was at
least −0.15 mmol/L (−0.50 mg/dL) with a SD of 0.5 mmol/L,
a significance level of 5%, a power of 80% and a 30% dropout
rate.
Statistical analysis
For the short-term phase, the primary efficacy analysis was
performed on the intent-to-treat population. Change in serum
phosphorus from Week 12 to Week 16 (or last observation
carried forward; LOCF) was analysed using analysis of covari-
ance (ANCOVA), with treatment and centre as factors, and
Week 12 serum phosphorus level as a covariate. Secondary
end points were analysed using the same ANCOVA model.
Tests of superiority were two-sided and at the 5% significance
level; differences between groups were presented with 95% CI.
During the short-term phase, a comparison of colestilan and
sevelamer tested for non-inferiority as a secondary end point;
if the upper limit of the 90% CI for the difference between the
drugs for change in serum phosphorus from baseline to Week
12 (LOCF) was less than +0.15 mmol/L (0.5 mg/dL) then
colestilan could be regarded as non-inferior to sevelamer.
Responder analyses were also performed.
For the long-term extension, efficacy and safety variables
were summarized using descriptive statistics. Changes from
baseline of the short-term phase to the end of the extension
phase were assessed for statistical significance (two-sided at
5% level) using a paired t-test. Responder analyses were also
performed.
RESULTS
The disposition of the patients who participated in the study is
shown in Figure 2. A total of 336 patients were randomized in
the short-term phase, 244 of whom completed the open-label
period. Among recipients of colestilan, 104 were re-rando-
mized and 98 completed the placebo-controlled withdrawal
period. Overall, 200 patients (124 from the sevelamer group
and 76 from the colestilan group) entered the long-term exten-
sion and 136 completed this phase.
Baseline characteristics at the start of the short-term phase
were similar between the groups (Table 1). Overall, most pa-
tients were Caucasian, the mean age of the population was 58
years, and there was a higher proportion of males than females
(61.9 versus 38.1%). Mean BMI was 27.1 kg/m2, and mean
weight before and after dialysis were 77.0 and 74.4 kg, respect-
ively. Characteristics were balanced between the treatment
groups. The baseline characteristics of patients who entered
the placebo-controlled period were consistent with the initial
profile, as were the characteristics of those patients who
entered the long-term extension. There were no notable
changes in the adequacy of dialysis in any group during the
study.
All but one patient had been receiving phosphate binder
therapy prior to the study; 67.6% had been taking one binder
and 32.1% more than one binder. The most commonly used
pre-study phosphate binders were calcium-based (71.3% of
the colestilan group and 77.8% of the sevelamer group), fol-
lowed by sevelamer (26.9% of the colestilan group and 32.3%
of the sevelamer group). Pre-existing lipid-modifying therapy
was continued by 41 and 49% of the colestilan and sevelamer
groups during the short-term phase. At the start of the long-
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term extension, 24% of the colestilan group and 50% of the
sevelamer group were taking lipid-modifying agents.
Phosphorus and calcium levels
At the end of the placebo-controlled withdrawal period
(Week 16), the mean serum phosphorus level was significantly
lower with colestilan than placebo (P < 0.001); Figure 3. Serum
phosphorus increased in patients who switched to placebo for
this period, whereas there was minimal change among those
who remained on colestilan (mean between-group difference
−1.32 mg/dL or 0.43 mmol/L; 95% CI −1.87, −0.78). Calcium
level did not alter in the colestilan group and there was no sig-
nificant difference compared with placebo for change in serum
calcium at Week 16. Ca × P was lower by 0.9 mmol/L in the
colestilan group compared with placebo (P < 0.001) and iPTH
was lowered by 7.09 pmol/L compared with placebo (P < 0.03);
Figure 3.
The efficacy of colestilan and sevelamer were compared as a
secondary end point. Both colestilan and sevelamer produced
a significant reduction from baseline in mean serum phos-
phorus level, which was maintained for up to 1 year (P <
0.001); Figure 4. Colestilan reduced serum phosphorus from
2.22 mmol/L (6.9 mg/dL) to 1.73 mmol/L (5.37 mg/dL) and
sevelamer from 2.36 mmol/L (7.32 mg/dL) to 1.61 mmol/L
(5.0 mg/dL) by the end of the study, for the population that
completed the study. The mean change from baseline for the
two phosphate binders was −0.47 mmol/L (−1.47 mg/dL) and
−0.73 mmol/L (−2.26 mg/dL) for colestilan and sevelamer, re-
spectively: both reductions were highly significant changes
from baseline (P < 0.001 in both cases). The responder rates
achieved with colestilan were similar to those seen with sevela-
mer, whether using 1.78 or 1.95 mmol/L as cut-off points for
responder analyses. Responder rates were 65.3% for colestilan
versus 66.9% for sevelamer with a cut-off of 1.78 mmol/L, and
73.3% for colestilan and 77.4% for sevelamer with 1.95 mmol/
L as the cut-off (Figure 5). However, due to the study design,
in the initial short-term phase, the non-inferiority of colestilan
to sevelamer could not be concluded according to the pre-spe-
cified criteria (mean change from baseline during the open-
label period was −0.42 mmol/L (−1.30 mg/dL) for
the colestilan group and −0.72 mmol/L (–2.22 mg/dL) for the
sevelamer group).
Baseline serum calcium levels were similar in the colestilan
and sevelamer groups. During the study, calcium levels tended
to be lower with colestilan than with sevelamer, largely
because serum calcium tended to increase from baseline in the
sevelamer group but not in the colestilan group (Figure 6).
After 1 year, calcium had decreased by 0.02 mmol/L (from a
F IGURE 2 : Patient disposition.
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baseline of 2.166 mmol/L) in the colestilan group but in-
creased by 0.035 mmol/L (from baseline 2.190 mmol/L) in the
sevelamer group.
Mean serum iPTH levels decreased from baseline to Week
12 in both colestilan and sevelamer groups. However, these re-
ductions were not maintained with long-term colestilan or se-
velamer treatment. There was an overall trend for mean serum
iPTH to increase. At Week 40 (LOCF), small mean increases
from baseline in serum iPTH were observed in both treatment
groups; 7.1 pmol/L for the colestilan-treated group (P < 0.3
versus baseline) and 0.9 pmol/L for sevelamer (P = not signifi-
cant). In the colestilan group, mean alkaline phosphatase in-
creased from 77.9 U/L at baseline to 115.7 U/L at study end
(mean change of +39.6 U/L). In the sevelamer group, mean al-
kaline phosphatase increased from 77.7 U/L at baseline to
115.5 U/L at study end (mean change +38.1 U/L).
Lipid levels
At the end of the placebo-controlled withdrawal period, the
mean serum low-density lipoprotein cholesterol (LDL-C) level
was significantly lower in the colestilan group than in the
group that switched to placebo (P < 0.001). Serum LDL-C in-
creased in the placebo group, whereas it remained relatively
stable in the colestilan group, giving a difference in the per cent
change in LDL-C level of −71.1%; Figure 7. Total cholesterol
level was also lower with colestilan compared with placebo (dif-
ference of −35.1%; P < 0.001), but there were no significant dif-
ferences in the levels of high-density lipoprotein cholesterol
(HDL-C) or triglycerides between the groups; Figure 7.
Both colestilan and sevelamer produced reductions from
baseline in serum LDL-C which were maintained for up to 1
year (P < 0.001; Figures 8 and 9). At Week 12 in the short-
term phase, the decrease was greater with colestilan than seve-
lamer (P < 0.05), and the proportions of patients who achieved
an LDL-C level <1.83 mmol/L (70 mg/dL) or <2.59 mmol/L
(100 mg/dL) were 50.0 and 91.9% for colestilan versus 50.8
and 87.9% for sevelamer. The proportions of responders re-
mained similar with colestilan (50.7 and 85.3%) and sevelamer
(54.0 and 80.6%) during long-term treatment.
Colestilan and sevelamer both reduced total cholesterol
level; the change was greater with colestilan at Week 12 in the
short-term phase study (difference between means −6.81%; P
< 0.001), but was fairly similar in both groups after 1 year
(Figure 9). Levels of HDL-C did not change significantly
during the 12 weeks of treatment with colestilan or sevelamer,
but increased slightly in both groups during long-term treat-
ment (Figure 9). There were no clear changes in the level of tri-
glycerides during the 12 weeks of treatment with either
colestilan or sevelamer; after 1 year, triglycerides had de-
creased in the colestilan group compared with a minimal in-
crease in the sevelamer group (Figure 9).
Other parameters
During the placebo-controlled withdrawal period there was
no notable change in mean HbA1c with either colestilan or
placebo (Table 2). During treatment with colestilan or sevela-
mer, mean HbA1c decreased slightly, and to a similar extent,
in both groups after 12 weeks and after 1 year (Table 2). The
decrease was observed primarily in those patients who had a
baseline HbA1c of ≥7.0% (Table 3).
At the end of the placebo-controlled withdrawal period,
serum uric acid level had decreased in the colestilan group but
not in the placebo group (difference −54.98 μmol/L; P < 0.001;
Table 3). Uric acid levels decreased to a similar extent with co-
lestilan and sevelamer after 12 weeks’ treatment. After 1 year,
the mean reduction from baseline in uric acid level was nu-
merically greater with colestilan (−66.68 μmol/L; P < 0.001)
than with sevelamer (−26.59 μmol/L; P < 0.001), although a
between-group statistical comparison was not performed.
Tolerability and safety
There was no notable difference in the incidence of treat-
ment-emergent AEs reported with colestilan and placebo (42.0
versus 45.3%). There were no notable differences between co-
lestilan and sevelamer in terms of the overall incidence of
treatment-emergent AEs during the titration period of the
short-term phase (84.0 versus 77.5%) or during long-term
treatment of up to 1 year (Table 4). AEs that led to discontinu-
ation of either study medication were generally related to the
gastrointestinal system, including diarrhoea, abdominal pain,
vomiting and nausea.
In terms of daily doses and number of tablets, from this
long-term study, it is possible to quantitate, in an approximate
way, the dosage of binders needed to produce an equivalent re-
duction in serum phosphate. At Week 16, when a virtually
identical reduction in serum phosphate was produced, the
doses of drugs used were 10.6 g/day for colestilan and 8.2 g/
day for sevelamer. Owing to the two medications’ differential
quantity of drug per tablet, this effectively results in the same
Table 1. Baseline characteristics
Parameter Colestilan (n = 162) Sevelamer (n = 169)
Age (years)
Mean (SD) 56.4 (14.7) 59.5 (13.8)
Median (range) 57 (19–88) 62 (22–89)
Age group, n (%)
<65 years 118 (72.8) 102 (60.4)
≥65 years 44 (27.2) 67 (39.6)
Gender, n (%)
Male 108 (66.7) 97 (57.4)
Female 54 (33.3) 72 (42.6)
Race, n (%)
Caucasian 142 (87.7) 150 (88.8)
Black 10 (6.2) 10 (5.9)
Asian 6 (3.7) 2 (1.2)
Other 4 (2.5) 7 (4.1)
BMI (kg/m2)
Mean (SD) 26.98 (4.44) 27.24 (5.32)
Median (range) 26.50 (15.2–37.4) 26.30 (16.6–41.3)
Type of dialysis, n (%)
Haemodialysis 151 (94.4) 159 (95.2)
Peritoneal
dialysis
9 (5.6) 8 (4.8)
Diabetic status, n (%)
Diabetes mellitus 47 (29.0) 51 (30.2)
No diabetes 115 (71.0) 118 (69.8)
BMI, body mass index; SD, standard deviation.
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F IGURE 3 : Calcium–phosphorus metabolism: change in serum levels of key parameters with colestilan (n = 50) versus placebo (n = 53) at the
end of the placebo-controlled withdrawal period (Week 12 to Week 16) [ITT].
F IGURE 4 : Mean serum phosphorus levels during 1 year of treatment with colestilan (n = 75) or sevelamer (n = 124) [ITT] (Error bars indicate
standard deviation).
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number of tablets/day. In the completer population at the end
of the study, these figures were 11.6 and 8.4 g, respectively.
DISCUSSION
Hyperphosphataemia in patients with CKD 5D is associated
with increased morbidity and mortality, and the reduction of
an elevated serum phosphorus level is considered beneficial
[6]. Furthermore, metabolic disturbances such as dyslipidae-
mia, impaired glucose control and hyperuricaemia may also be
associated with an increased risk of cardiovascular morbidity
in CKD patients, and correcting these abnormalities could be
appropriate in some patients [19, 25–28]. Most patients with
advanced CKD need medication, in the form of phosphate
binders, to help control their phosphorus levels. However,
hypercalcaemia can be a concern with calcium-based binders
[2, 11]. Furthermore, some calcium-free phosphate binders,
including sevelamer and the new binder colestilan, exert
beneficial effects on other parameters, such as lipids [17, 24],
which could be a useful additional therapeutic feature for
some CKD patients.
The current study incorporated a short-term comparison
of the efficacy of colestilan versus placebo and a long-term
comparison with sevelamer (in which efficacy was a secondary
end point). It showed that colestilan, a novel non-absorbable,
calcium-free, anion-exchange resin phosphate binder, was su-
perior to placebo at controlling serum phosphorus levels in pa-
tients receiving dialysis. Furthermore, the reductions in serum
phosphorus seen with colestilan were maintained during 1
year of treatment, and the proportion of patients achieving
target serum phosphorus levels at the end of the study was
similar with colestilan and sevelamer.
During the placebo-withdrawal period, the reduction in
mean serum phosphorus level that had been achieved during
the preceding 12-week dose titration period was maintained in
patients who continued to receive colestilan, whereas the phos-
phorus-lowering effect was lost in those who switched to
placebo. There was no significant difference in serum calcium
levels between the colestilan and placebo groups during the
placebo-withdrawal period, confirming that colestilan did not
alter serum calcium levels. In addition, serum total cholesterol
and LDL-C levels, which had decreased during colestilan titra-
tion, were significantly lower among patients who continued
on colestilan than among those who switched to placebo.
These findings are consistent with the results from previous
studies with colestilan [24, 29].
High serum levels of phosphorus are associated with an in-
creased risk of morbidity and mortality in patients with CKD
[4, 30–33]. Although there is a lack of data from large rando-
mized trials to show that treating hyperphosphataemia
reduces the risk of death in patients with kidney failure, obser-
vational data from DOPPS and the COSMOS study suggest
F IGURE 5 : Serum phosphorus responder rates after 1 year of
treatment with colestilan versus sevelamer [ITT].
F IGURE 6 : Mean serum calcium levels during 1 year of treatment with colestilan (n = 75) versus sevelamer (n = 124) [ITT].
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F IGURE 7 : Serum lipid levels: mean % change with colestilan (n = 50) versus placebo (n = 53) at the end of the placebo-controlled withdrawal
period (Week 12 to Week 16) [ITT].
F IGURE 8 : Mean % change from baseline in serum LDL-C level during 1 year of treatment with colestilan (n = 75) versus sevelamer (n = 124)
[ITT].
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that phosphate binder treatment is associated with a reduced
risk of death in patients on dialysis [8, 9], as does a prospective
cohort study of incident haemodialysis patients [7]. Further-
more, a small randomized study in non-dialysis patients found
that sevelamer improved survival compared with calcium-
based binders [34]. To achieve a noticeable benefit in major
outcomes, reductions in serum phosphorus levels need to be
sustained over the long-term. In the current study, both coles-
tilan and sevelamer produced statistically and clinically signifi-
cant reductions from baseline in serum phosphorus levels
which were maintained during up to 1 year of treatment.
The optimal target level for serum phosphorus is not
known, but it is recommended that serum phosphorus should
be reduced ‘toward’ a level of 1.13–1.78 mmol/L (3.5–5.5 mg/
dL) in dialysis patients [6, 35]. It is recognized that this target
level may only be achieved in around 60% of patients [36].
After 1 year in the current study, just over 65% of patients in
both the colestilan and the sevelamer groups had a phos-
phorus level ≤1.78 mmol/L (5.5 mg/dL). A level of ≤1.95
mmol/L (6.0 mg/dL) was achieved by more than 70% of both
groups.
Calcium-based phosphate binders can be associated with
hypercalcaemia and an increased risk of vascular calcification
[2, 11]. Calcium-free binders, such as sevelamer and lan-
thanum, may reduce the risk of hypercalcaemia and the
progression of vascular calcification [13–16]. The new
calcium-free binder colestilan also reduces the risk of hypercal-
caemia and thus possibly the progression of vascular calcifica-
tions. In the current study, serum calcium levels remained
stable in the colestilan group throughout the 1-year study
period. Interestingly, calcium levels tended to increase slightly
in the sevelamer group during the same period. Both sevelamer
and colestilan are non-absorbable, calcium-free, anion-ex-
change resins; nonetheless, there may be differences in the
actions of these agents. Sevelamer is generally associated with a
reduction in serum calcium levels and the risk of hypercalcae-
mia compared with calcium-based binders [13, 37], and some
studies suggest it reduces vascular calcification [14, 15].
However, the differences seen in the present study could have a
clinical impact, and further evaluation in controlled trials may
be worthwhile.
Lipid profile is known to be altered in advanced CKD.
CKD 5D patients usually display increased concentrations of
intact or partially metabolized triglyceride-rich lipoproteins,
reduced serum levels of HDL-cholesterol and elevated concen-
trations of Lp(a). The subfractionation of apolipoprotein B-
containing lipoproteins usually reveals a predominance of
small, dense LDL particles with a dysregulation of the synthe-
sis and activity of HDL leading to decreased plasma levels
[38]. In addition the anti-inflammatory functions of HDL
F IGURE 9 : Serum lipid levels: mean % change after 1 year of treatment with colestilan (n = 75) versus sevelamer (n = 124) [ITT].
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(such as its ability to inhibit LDL oxidation) are defective in
these patients [39]. More than half of dialysis patients have a
level of LDL-C ≥2.59 mmol/L (100 mg/dL) [20]. Although
several studies have failed to show a benefit for lowering LDL-
C in haemodialysis patients in terms of major clinical out-
comes, one study found that simvastatin/ezetimibe reduced
major atherosclerotic events by 17% in CKD patients [19].
In the current study, both colestilan and sevelamer were
associated with significant reductions in serum total choles-
terol and LDL-C levels during long-term treatment, and
after 1 year a serum LDL-C level <2.59 mmol/L (100 mg/dL)
was achieved in more than 50% of patients and a level of
<1.83 mmol/L (70 mg/dL) in more than 80%. The potential
to reduce LDL-C levels without adding a separate medica-
tion which would increase the tablet burden could be of use
in some CKD patients.
In addition to their lipid-lowering effect, bile acid seques-
trants can also affect glycaemic control through their interac-
tions with receptors involved in both lipid and glucose
metabolic pathways [40]. In our study, colestilan lowered
HbA1c in patients who had a baseline value ≥7.0%, as did se-
velamer. Although the number of patients in each subgroup is
relatively low (11 and 22) this finding has been noted previ-
ously with colestilan [24]. Levels of uric acid also decreased
during treatment with colestilan. The mechanism by which
colestilan reduces uric acid is not known, but a similar effect
was seen with sevelamer in this study. An association between
hyperuricaemia and cardiovascular disease has been noted
[41, 42], and hyperuricaemia may also adversely affect renal
function [43, 44]. Uric acid levels increase with declining renal
function, and consequently hyperuricaemia is present in many
patients with CKD [43]. However, it is not yet clear what effect
reducing uric acid levels has in terms of preventing
Table 2. Changes in HbA1c and uric acid during the study
Placebo-controlled period Colestilan (n = 50) Placebo (n = 53) P (between-group)
HbA1c (%)a
Baseline (Week 12) 5.58 5.79
Change at Week 16 −0.01 +0.05 –
Uric acid (μmol/L)
Baseline (Week 12) 359.4 347.3
Change at Week 16 −8.72 +46.26 <0.001
Active-controlled period Colestilan (n = 160) Sevelamer (n = 167)
HbA1c (%)a
Baseline (Week 0) 6.02bb/5.97c 6.11b/6.12c
Change at Week 12d −0.24 −0.32 –
Change at Week 52–56e −0.41 −0.37 –
Uric acid (μmol/L)
Baseline (Week 0) 399.5b/413.0c 385.2b/386.7c
Change at Week 12d −38.87 −27.77 0.075
Change at Week 52–56e −66.68f −26.59f –
aStatistical analysis was not performed for HbA1c.
bBaseline value for patients randomized into short-term phase (colestilan 160, sevelamer 167).
cBaseline for patients who participated in both the short-term and extension phases (colestilan 75, sevelamer 124).
dChange from baseline for patients randomized into the short-term phase.
eChange from baseline for patients who participated in both the short-term and extension phases.
fP < 0.001 versus baseline.
Table 3. Mean change from baseline in HbA1c after 1 year by baseline
HbA1c level
Baseline HbA1c category Mean (SD) serum HbA1c (mg/dL)
Colestilan (n = 76) Sevelamer (n = 124)
<7.0% total haemoglobin
n = 64 n = 102
Baseline 5.68 (0.58) 5.74 (0.59)
End of study 5.37 (0.53) 5.54 (0.52)
Mean change –0.30 (0.64) –0.20 (0.53)
≥7.0% total haemoglobin
n = 11 n = 22
Baseline 7.63 (0.59) 7.87 (1.11)
End of study 6.50 (0.71) 6.73 (1.07)
Mean change –1.08 (0.77) –1.14 (1.13)
SD, standard deviation.
Table 4. Adverse events from baseline to end of extension
Category Colestilan (n = 76) Sevelamer (n = 124)
At least one TEAE
Patients, n (%) 76 (100.0) 116 (93.5)
Events, n 692 935
At least one serious TEAE
Patients, n (%) 31 (40.8) 48 (38.7)
Events, n 69 96
At least one treatment-related TEAE
Patients, n (%) 33 (43.4) 40 (32.3)
Events, n 68 72
At least one severe TEAE
Patient, n (%) 17 (22.4) 22 (17.7)
TEAE, treatment-emergent adverse event.
O
R
IG
IN
A
L
A
R
T
IC
L
E
1070 F. Locatelli et al.
cardiovascular disease or the progression of renal disease in
CKD patients [45].
Colestilan was generally well tolerated during 1 year of
treatment, and the overall safety profile was similar for colesti-
lan and sevelamer. AEs were commonly gastrointestinal in
nature, which would be consistent with the mode of action of
the drugs.
Study limitations
Although this study demonstrates for the first time a long-
term reduction in serum phosphorus and LDL-C in CKD 5D
patients with hyperphosphataemia treated with colestilan, and
indicates no substantial difference in phosphate reduction
between colestilan and sevelamer after 1 year, early timepoints
did show some difference that could well have been due to the
study design. In this study, almost one-third of randomized
patients had previously been receiving sevelamer; and thus, it
could be considered that the patient pool used was substantial-
ly ‘sevelamer-biased’, in that these patients were already
known to tolerate sevelamer and were patients for whom seve-
lamer was an effective treatment. In addition, a substantial
percentage of patients were taking multiple therapies for redu-
cing serum phosphate, suggesting that one drug alone would
not be sufficient to reduce phosphate to an acceptable level.
One other limitation of this study that should be considered is
that only part of the study was blinded—the 4-week placebo-
withdrawal period. Although these study limitations should be
considered alongside the results, it is unlikely that they would
alter the overall conclusions, and may well suggest that the
study underestimates the effect and the tolerability of colestilan
in these patients in comparison to sevelamer.
CONCLUSION
In conclusion, after short-term titration, colestilan produced a
significant reduction in serum phosphorus, LDL-C and uric
acid levels compared to placebo, while long-term treatment
maintained a clinically relevant reduction in serum phos-
phorus levels for 1 year, and was generally well tolerated. The
results with colestilan were generally consistent with those
seen with sevelamer. This long-term study indicates that coles-
tilan is a safe and effective treatment for hyperphosphataemia
in patients with CKD 5D.
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